The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses

Jill Bayliss, Amy Hilger, Prakash Vishnu, Kathleen Diehl, Dorraya El-Ashry

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Loss of estrogen receptor α ERα in breast cancer correlates with a more aggressive, tamoxifen resistant phenotype. ERα-negative tumors often display overexpression or amplification of growth factor receptors of the erbB family, particularly EGFR and erbB-2, and consequently, elevated growth factor signaling and resultant MAP kinase (ERK) activity. We have previously shown that overexpression/hyperactivation of EGFR or erbB-2, or the downstream effectors Raf or MEK, in ERα+, estrogen-dependent MCF-7 cells results in the acquisition of estrogen-independence and loss of ERα expression. We have shown that the common downstream effector of ERα downregulation in all our model cell lines is hyperactive MAPK and that inhibition of this hyperactive MAPK restores ERα expression. Microarray expression profiling of these hyperactive MAPK model cell lines revealed a hyperactive MAPK signature that correlates with ERα-breast cancer and not ERα+ breast cancer. We have more recently extended these observations to established ERα-breast cancer cell lines and primary cultures from ERα-breast tumor specimens. Inhibition of MAPK in these ERα-breast cancer cells restores ERα expression and associated with this re-expression of ERα is the acquisition of anti-estrogen responses. These data demonstrate the dynamic nature of ERα expression in breast cancer cells and the ability to impact ERα expression by altering cellular signaling pathways. Further, they suggest a potential novel therapeutic strategy for ERα-breast cancer: inhibition of MAPK activity to restore both ERα expression and anti-estrogen responses.

Original languageEnglish
Title of host publicationtTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets
PublisherSpringer Netherlands
Pages39-61
Number of pages23
ISBN (Print)9781402085253
DOIs
StatePublished - Dec 1 2009

Fingerprint

Estrogen Receptors
Estrogens
Breast Neoplasms
Cell Line
Growth Factor Receptors
Mitogen-Activated Protein Kinase Kinases
MCF-7 Cells
Tamoxifen
Intercellular Signaling Peptides and Proteins
Phosphotransferases
Down-Regulation
Phenotype
Neoplasms

Keywords

  • Estrogen receptor loss
  • MAPK
  • Microarray profiling

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bayliss, J., Hilger, A., Vishnu, P., Diehl, K., & El-Ashry, D. (2009). The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses. In tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets (pp. 39-61). Springer Netherlands. https://doi.org/10.1007/978-1-4020-8526-0_3

The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses. / Bayliss, Jill; Hilger, Amy; Vishnu, Prakash; Diehl, Kathleen; El-Ashry, Dorraya.

tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands, 2009. p. 39-61.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bayliss, J, Hilger, A, Vishnu, P, Diehl, K & El-Ashry, D 2009, The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses. in tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands, pp. 39-61. https://doi.org/10.1007/978-1-4020-8526-0_3
Bayliss J, Hilger A, Vishnu P, Diehl K, El-Ashry D. The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses. In tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands. 2009. p. 39-61 https://doi.org/10.1007/978-1-4020-8526-0_3
Bayliss, Jill ; Hilger, Amy ; Vishnu, Prakash ; Diehl, Kathleen ; El-Ashry, Dorraya. / The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses. tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. Springer Netherlands, 2009. pp. 39-61
@inbook{31325ee560fd482c91febcf6cdb41c73,
title = "The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses",
abstract = "Loss of estrogen receptor α ERα in breast cancer correlates with a more aggressive, tamoxifen resistant phenotype. ERα-negative tumors often display overexpression or amplification of growth factor receptors of the erbB family, particularly EGFR and erbB-2, and consequently, elevated growth factor signaling and resultant MAP kinase (ERK) activity. We have previously shown that overexpression/hyperactivation of EGFR or erbB-2, or the downstream effectors Raf or MEK, in ERα+, estrogen-dependent MCF-7 cells results in the acquisition of estrogen-independence and loss of ERα expression. We have shown that the common downstream effector of ERα downregulation in all our model cell lines is hyperactive MAPK and that inhibition of this hyperactive MAPK restores ERα expression. Microarray expression profiling of these hyperactive MAPK model cell lines revealed a hyperactive MAPK signature that correlates with ERα-breast cancer and not ERα+ breast cancer. We have more recently extended these observations to established ERα-breast cancer cell lines and primary cultures from ERα-breast tumor specimens. Inhibition of MAPK in these ERα-breast cancer cells restores ERα expression and associated with this re-expression of ERα is the acquisition of anti-estrogen responses. These data demonstrate the dynamic nature of ERα expression in breast cancer cells and the ability to impact ERα expression by altering cellular signaling pathways. Further, they suggest a potential novel therapeutic strategy for ERα-breast cancer: inhibition of MAPK activity to restore both ERα expression and anti-estrogen responses.",
keywords = "Estrogen receptor loss, MAPK, Microarray profiling",
author = "Jill Bayliss and Amy Hilger and Prakash Vishnu and Kathleen Diehl and Dorraya El-Ashry",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-1-4020-8526-0_3",
language = "English",
isbn = "9781402085253",
pages = "39--61",
booktitle = "tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets",
publisher = "Springer Netherlands",

}

TY - CHAP

T1 - The re-expression of estrogen receptor in estrogen receptor-negative breast cancer and restoration of anti-estrogen responses

AU - Bayliss, Jill

AU - Hilger, Amy

AU - Vishnu, Prakash

AU - Diehl, Kathleen

AU - El-Ashry, Dorraya

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Loss of estrogen receptor α ERα in breast cancer correlates with a more aggressive, tamoxifen resistant phenotype. ERα-negative tumors often display overexpression or amplification of growth factor receptors of the erbB family, particularly EGFR and erbB-2, and consequently, elevated growth factor signaling and resultant MAP kinase (ERK) activity. We have previously shown that overexpression/hyperactivation of EGFR or erbB-2, or the downstream effectors Raf or MEK, in ERα+, estrogen-dependent MCF-7 cells results in the acquisition of estrogen-independence and loss of ERα expression. We have shown that the common downstream effector of ERα downregulation in all our model cell lines is hyperactive MAPK and that inhibition of this hyperactive MAPK restores ERα expression. Microarray expression profiling of these hyperactive MAPK model cell lines revealed a hyperactive MAPK signature that correlates with ERα-breast cancer and not ERα+ breast cancer. We have more recently extended these observations to established ERα-breast cancer cell lines and primary cultures from ERα-breast tumor specimens. Inhibition of MAPK in these ERα-breast cancer cells restores ERα expression and associated with this re-expression of ERα is the acquisition of anti-estrogen responses. These data demonstrate the dynamic nature of ERα expression in breast cancer cells and the ability to impact ERα expression by altering cellular signaling pathways. Further, they suggest a potential novel therapeutic strategy for ERα-breast cancer: inhibition of MAPK activity to restore both ERα expression and anti-estrogen responses.

AB - Loss of estrogen receptor α ERα in breast cancer correlates with a more aggressive, tamoxifen resistant phenotype. ERα-negative tumors often display overexpression or amplification of growth factor receptors of the erbB family, particularly EGFR and erbB-2, and consequently, elevated growth factor signaling and resultant MAP kinase (ERK) activity. We have previously shown that overexpression/hyperactivation of EGFR or erbB-2, or the downstream effectors Raf or MEK, in ERα+, estrogen-dependent MCF-7 cells results in the acquisition of estrogen-independence and loss of ERα expression. We have shown that the common downstream effector of ERα downregulation in all our model cell lines is hyperactive MAPK and that inhibition of this hyperactive MAPK restores ERα expression. Microarray expression profiling of these hyperactive MAPK model cell lines revealed a hyperactive MAPK signature that correlates with ERα-breast cancer and not ERα+ breast cancer. We have more recently extended these observations to established ERα-breast cancer cell lines and primary cultures from ERα-breast tumor specimens. Inhibition of MAPK in these ERα-breast cancer cells restores ERα expression and associated with this re-expression of ERα is the acquisition of anti-estrogen responses. These data demonstrate the dynamic nature of ERα expression in breast cancer cells and the ability to impact ERα expression by altering cellular signaling pathways. Further, they suggest a potential novel therapeutic strategy for ERα-breast cancer: inhibition of MAPK activity to restore both ERα expression and anti-estrogen responses.

KW - Estrogen receptor loss

KW - MAPK

KW - Microarray profiling

UR - http://www.scopus.com/inward/record.url?scp=84889987206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889987206&partnerID=8YFLogxK

U2 - 10.1007/978-1-4020-8526-0_3

DO - 10.1007/978-1-4020-8526-0_3

M3 - Chapter

SN - 9781402085253

SP - 39

EP - 61

BT - tTherapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets

PB - Springer Netherlands

ER -